Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT… EP News Bureau Dec 10, 2024 ISB 2001 demonstrated an ORR of 83 per cent in heavily pretreated patients treated at active doses (0.05 mg/kg and higher)
